QIAGEN powered by

Custom Real-World Insights Projects

Create and deliver bespoke Real-World Insights (RWI) projects with a range of flexible options and services tailored to your unique requirements

Design trials with enriched patient populations

At QIAGEN, we don’t just deliver real-world data, we leverage the latest technology, advanced analytics and clinical knowledge to generate insights that enable accelerated market access for new drug therapies. 

With QIAGEN RWI, you can use real-world data to:

  • Analyze the prevalence of co-occurring biomarkers
  • Understand the molecular profiles of a real-world population
  • Incorporate a quality-managed database into your CDx workflow to classify novel variants identified by the diagnostic assay
  • Associate genomic and diagnostic profiles to support reimbursement plans
  • Design a project targeting rare cancer types


QIAGEN is helping to take cancer drug development to the next level by aligning the real-world data and comprehensive analyses needed to support biomarker and indication selection for trial stratification and CDx labeling with the superior technical design, regulatory expertise, and manufacturing excellence that are required to deliver the precision CDx that will identify the patients who will derive the most benefit from the targeted therapies.

Sheryl Elkin, Ph.D.,
Chief Scientific Officer at N-of-One, a QIAGEN company

Leverage Real-World Insights

QIAGEN’s RWI portfolio combines robust real-world data from over 200,000 cancer cases and advanced analytics to achieve better decisions faster in early drug and test development.

To access RWI, you can: 

Get started today

Do you have novel questions, hypotheses, and hurdles to overcome? Our team of scientists, bioinformaticists, and clinicians can help you strategize, customize, and deliver within your timeline.

Biomarker and Indication Selection​

Choose the best biomarkers and cancer indications for your molecularly targeted therapies​

Cohort Stratification and CDx Design

Identify appropriate patient cohorts and enhance your CDx design to improve stratification and success

Molecular Profiling and Response Analyses

Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses